Fast Visual Field Progression Is Associated with Depressive Symptoms in Patients with Glaucoma

Abstract

Purpose To evaluate the association between rates of progressive visual field loss and the occurrence of depressive symptoms in patients with glaucoma followed over time. Design Prospective observational cohort study. Participants The study included 204 eyes of 102 patients with glaucomatous visual field defects on standard automated perimetry (SAP). Methods All patients had Geriatric Depression Scale (GDS) questionnaires and visual field tests obtained over a mean follow-up time of 2.2 ± 0.6 years. Change in depressive symptoms was assessed by calculating the difference between GDS scores at the last follow-up visit from those at baseline. Rates of visual field loss were assessed by SAP. An integrated binocular visual field was estimated from the monocular SAP tests and rates of change in mean sensitivity (MS) over time were obtained from linear mixed models. Regression models were used to investigate the association between progressive visual field loss and changes in depressive symptoms, adjusting for potentially confounding clinical and socioeconomic variables. Main Outcome Measures The association between rates of change in binocular SAP MS and change in GDS questionnaire scores. Results There was a significant correlation between change in the GDS scores during follow-up and change in binocular SAP sensitivity. Each 1 dB/year change in binocular SAP MS was associated with a change of 2.0 units in the GDS scores during the follow-up period (P = 0.025). In a multivariable model adjusting for baseline disease severity, change in visual acuity, age, gender, race, Montreal Cognitive Assessment score, education, income, and comorbidity index, each 1 dB/year change in binocular SAP MS was associated with a change of 3.0 units in the GDS score (P = 0.019). Conclusions Faster visual field progression was associated with the occurrence of depressive symptoms in patients with glaucoma.

Human Emotions on the Onset of Cardiovascular and Small Vessel Related Diseases

“…In another study Visual function was associated with depressive symptomatology but not the degree of impairment of visual acuity (67). Severe visual impairment beyond the level required to be registered blind may not add further the sense of loss, so the gradual visual loss allows the adaptation.…”

The relationship between vision impairment and well‐being among centenarians: findings from the Georgia Centenarian Study

“…The results of the multiple regression analyses indicated that depression was associated with subjective vision in the same way as in the model of objective vision; however, we did not find a relationship between subjective vision and loneliness. Visual impairment has a profound negative impact on daily life (Evans, Fletcher, and Wormald, 2007;Hayman et al, 2007) and affects depression (Bookwala and Lawson, 2011;Diniz-Filho et al,2016;Van Nispen et al, 2016). It became clear that visual function impacts centenarians' SWB in the model controlled by residential status.…”

“…Several studies have indicated that vision affects SWB among older adults (Crews, ; Horowitz, ; Jopp, Rott, and Oswald, ; O'Donnell, ). Poor vision is related to life satisfaction (Bourque et al , ; Reinhardt, ), subjective health (Femia, Zarit, and Johansson, ), and depression (Bookwala and Lawson, ; Diniz‐Filho et al , ; Van Nispen et al , ). Visual function also impacts social activity, which promotes SWB among oldest‐old adults.…”

“…Several studies have indicated that vision affects SWB among older adults (Crews, 1994;Horowitz, 2004;Jopp, Rott, and Oswald, 2008;O'Donnell, depression (Bookwala and Lawson, 2011;Diniz-Filho et al, 2016;Van Nispen et al, 2016). Visual function also impacts social activity, which promotes SWB among oldest-old adults.…”

Critical evaluation of latanoprostene bunod in the treatment of glaucoma

“…Profound disease and faster rate of visual field loss are also associated with poorer patient psychological outcomes 82. Accordingly, the need for effective treatment regimens that halt disease progression without further impairing the quality of life and overall well-being is paramount.…”